1. How will enteral potassium be administered to patients with hypokalemia during mechanical ventilation? These patients are often sedated, resulting in reduced gastrointestinal motility that can impair absorption of enteral doses of potassium. 2. The randomization scheme is confusing and may be better illustrated with a figure. 3. When will potassium levels be measured after administration of intravenous or enteral potassium? 4. What will determine failure of treatment in either arm? When will cross over be allowed? 5. How will differences in the use of diuretics between the 2 groups be accounted for? Differences in diuretic dosing may impact the serum potassium levels and need for replacement? 6. The serum potassium levels when potassium supplementation is undertaken is a lot lower than whet is proposed in this protocol. I am not sure a serum potassium level of < 4.4 will result in prescribing potassium supplementation. Most providers will only replace at much lower levels. 7. "Objectives" should be changes to study "Outcomes" as this is more conventional. The authors should categorize their outcomes into primary and secondary efficacy and safety outcomes to improve clarity. Also the secondary outcomes can include clinical end-points such as length of stay in the ICU or Hospital. 8. How will repeated inclusion of patient levels variables be handled in the analysis of data? 9. The dosing scheme for Intravenous potassium replacement should include a maximum dose. I am concerned about giving "mini-doses" of KCL through a CVL as described on the paper. Should a K of 4 be really replaced?
REVIEWER
In clinical practice this is rarely done. Suggest change the Trigger: for K replacement to 3.5 mEq. Also suggest to have a uniform test be applied to the blood sample: (different values are obtained when using POC testing at bedside vs. sending to the central laboratory)
VERSION 1 -AUTHOR RESPONSE
Reviewer Name Ravi Thiagarajan Institution and Country Boston Children's Hospital Cardiac Intensive Care Unit USA 1. How will enteral potassium be administered to patients with hypokalemia during mechanical ventilation? These patients are often sedated, resulting in reduced gastrointestinal motility that can impair absorption of enteral doses of potassium. Response:
The following statement has been added to the study procedure and monitoring section on page 11 "A nasogastric feeding tube is regularly placed in our mechanically ventilated and sedated pediatric patients. These tubes were used to administer oral potassium supplementation in these patients."
2. The randomization scheme is confusing and may be better illustrated with a figure.
Response: This following figure has been added to the manuscript as Figure 1 on page 7
3. When will potassium levels be measured after administration of intravenous or enteral potassium? Response: This has been mentioned in the manuscript. "As per previously established protocol and bioavailability data, repeat serum potassium will be sent 1 hour after replacement in the IVPR group and 2 hours after replacement in the EPR group." on Page 11
4. What will determine failure of treatment in either arm? When will cross over be allowed?
Response: This statement is added to the manuscript "EPR patients who develop side effects (e.g. vomiting GI upset) with subsequent need to parenteral potassium supplementation or who develop critically low levels of potassium<2mEq (exclusion criteria) on enteral supplementation will be allowed to cross over and receive IVPR subsequently. An intention to treat analysis will be performed to account for cross over patients. ." on Page 10 This detail is also present in Figure 1 5. How will differences in the use of diuretics between the 2 groups be accounted for? Differences in diuretic dosing may impact the serum potassium levels and need for replacement? Response:
The following statement has been added to the manuscript "Diuretic dosing is a component of the data collection and dosage of diuretics in mg/kg/hour will be calculated for each episode. The process of block randomization should help an equal distribution between the two groups. At the analysis level, a multivariate linear regression will be performed to account for confounding variables like diuretic or inotropic use" on Page 17
6. The serum potassium levels when potassium supplementation is undertaken is a lot lower than what is proposed in this protocol. I am not sure a serum potassium level of < 4.4 will result in prescribing potassium supplementation. Most providers will only replace at much lower levels. Response: These cut offs were decided based on the following study which proposes using higher potassium levels > 4.5 Meq/L in cardiovascular patients. 7. "Objectives" should be changes to study "Outcomes" as this is more conventional. The authors should categorize their outcomes into primary and secondary efficacy and safety outcomes to improve clarity. Also the secondary outcomes can include clinical end-points such as length of stay in the ICU or Hospital. We agree with the reviewer. The term "objectives" has been changed to "outcomes" on Pages 2, 5,16 and 17. We agree that secondary outcomes like length of stay in the ICU and hospital are important end points but are effected by several factors i.e. disease severity, surgical expertise, infections, preoperative nutritional status etc. For the purpose of this study controlling for so many confounding factors may require much larger number of patients. Since our power calculation was done on events of hypokalemia, the number of patients required was manageable. Thus for the purpose of this study we decided to leaves these secondary outcomes out. We will still gather the data and present it but will not perform any analysis on it.
8. How will repeated inclusion of patient levels variables be handled in the analysis of data? Response: The question is not clear to us but if it pertains to patient demographic variables then those will be analyzed only once on a patient to patient basis. For potassium level analysis, cumulative data from events and episodes of hypokalemia will be analyzed. A statement is added clarifying this on page 17.
9. The dosing scheme for Intravenous potassium replacement should include a maximum dose.
Response: We agree with the reviewer that maximum doses of both the forms should be a part of the protocol. The following statement are present in the manuscript. Research question well stated methods appropriate.
Replacing K when is normal is not common in clinical practice.
